BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase
It is unclear if patients with CML treated with imatinib who fail to achieve BCR/ABL transcript
levels< 10% IS at 3 months ie an early molecular response (EMR) have a better prognosis if …
levels< 10% IS at 3 months ie an early molecular response (EMR) have a better prognosis if …
Efficacy of low-dose imatinib in chronic-phase chronic myelogenous leukemia patients
S Kobayashi, F Kimura, A Kobayashi, K Sato… - Annals of …, 2009 - Springer
Imatinib mesylate is very effective in the treatment of chronic myelogenous leukemia (CML)
and 400 mg/day imatinib is considered the standard treatment dose for chronic-phase (CP) …
and 400 mg/day imatinib is considered the standard treatment dose for chronic-phase (CP) …
Baseline BCR-ABL1 transcript type of e13a2 and large spleen size are predictors of poor long-term outcomes in chronic phase chronic myeloid leukemia patients who …
SE Lee, SY Choi, SH Kim, HY Song, HL Yoo… - Leukemia & …, 2018 - Taylor & Francis
We conducted this study to identify the factors for predicting poor outcomes in chronic
myeloid leukemia patients who failed to achieve a 3-month early molecular response (EMR) …
myeloid leukemia patients who failed to achieve a 3-month early molecular response (EMR) …
BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate–treated patients with CML
RD Press, Z Love, AA Tronnes, R Yang, T Tran… - Blood, 2006 - ashpublications.org
Although most patients with chronic myeloid leukemia (CML) treated with imatinib mesylate
achieve a complete cytogenetic response (CCR), some patients will relapse. To determine …
achieve a complete cytogenetic response (CCR), some patients will relapse. To determine …
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
Recent studies have demonstrated that some patients with chronic myeloid leukemia (CML)
can maintain remission after discontinuation of imatinib. A prerequisite is stable …
can maintain remission after discontinuation of imatinib. A prerequisite is stable …
Early landmark analysis of imatinib treatment in CML chronic phase: Less than 10% BCR‐ABL by FISH at 3 months associated with improved long‐term clinical …
L Ohm, I Arvidsson, G Barbany, R Hast… - American journal of …, 2012 - Wiley Online Library
Imatinib has dramatically improved the clinical outcome in chronic myeloid leukemia,
chronic phase (CMLcp), but a risk of resistance and serious disease progression still …
chronic phase (CMLcp), but a risk of resistance and serious disease progression still …
Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib
The aim of this phase IV study was to (1) to define efficacy of escalating dose imatinib in
chronic myeloid leukemia (CML) patients showing suboptimal response to standard dose …
chronic myeloid leukemia (CML) patients showing suboptimal response to standard dose …
Molecular responses of late chronic phase chronic myeloid leukemia patients after achieving complete cytogenetic responses with imatinib treatment: a 6-year follow …
YZ Qin, B Jiang, Q Jiang, H Jiang, JL Li, Y Zhang… - Annals of …, 2009 - Springer
To explore the long-term efficacy of imatinib to chronic myeloid leukemia, a total of 46 late
chronic phase (CP) patients were assessed after achieving complete cytogenetic response …
chronic phase (CP) patients were assessed after achieving complete cytogenetic response …
Discontinuation of imatinib therapy in chronic myeloid leukemia patients with sustained complete molecular response4. 5 (CMR4. 5)
Abstract Abstract 2763 Approximately 50% of CP CML patients achieve complete molecular
response (CMR) at 6–7 years of first-line imatinib therapy. Although imatinib therapy is …
response (CMR) at 6–7 years of first-line imatinib therapy. Although imatinib therapy is …
BCR-ABL Levels Continue To Decrease up to 42 Months after Commencement of Standard Dose Imatinib in Patients with Newly Diagnosed Chronic Phase CML Who …
S Branford, Z Rudzki, A Grigg, JF Seymour, K Taylor… - Blood, 2004 - Elsevier
The dose of 400mg per day of imatinib is currently considered standard therapy for patients
with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP). The IRIS trial …
with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP). The IRIS trial …